David M. Berman - 17 Feb 2026 Form 4 Insider Report for Immunocore Holdings plc (IMCR)

Role: HEAD OF R&D
Signature: /s/ Lily Hepworth, Attorney-in-Fact
Issuer symbol: IMCR
Transactions as of: 17 Feb 2026
Net transactions value: -$192,968
Form type: 4
Filing time: 19 Feb 2026, 17:00:12 UTC
Previous filing: 08 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Berman David M	HEAD OF R&D	C/O IMMUNOCORE HOLDINGS PLC, 92 PARK DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE, UNITED KINGDOM	/s/ Lily Hepworth, Attorney-in-Fact	19 Feb 2026	0001955244

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMCR	Ordinary Shares	Options Exercise	$0	+11,824		$0.000000	11,824	17 Feb 2026	Direct	F1
transaction	IMCR	Ordinary Shares	Sale	$192,968	-5,965	-50%	$32.35	5,859	18 Feb 2026	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMCR	Restricted Share Units	Options Exercise	$0	-11,824	-25%	$0.000000	35,473	17 Feb 2026	Ordinary Shares	11,824		Direct	F1, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share.
F2	The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock units ("RSUs").
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $32.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	Each RSU represents a contingent right to receive one Ordinary Share.
F5	On February 17, 2025, the Reporting Person was granted 47,297 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.